GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (LTS:0LB2) » Definitions » Shiller PE Ratio

Supernus Pharmaceuticals (LTS:0LB2) Shiller PE Ratio : 20.80 (As of May. 16, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Supernus Pharmaceuticals Shiller PE Ratio?

As of today (2024-05-16), Supernus Pharmaceuticals's current share price is $28.70. Supernus Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $1.38. Supernus Pharmaceuticals's Shiller PE Ratio for today is 20.80.

The historical rank and industry rank for Supernus Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

LTS:0LB2' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.55   Med: 38.05   Max: 79.92
Current: 20.49

During the past years, Supernus Pharmaceuticals's highest Shiller PE Ratio was 79.92. The lowest was 18.55. And the median was 38.05.

LTS:0LB2's Shiller PE Ratio is ranked better than
60.11% of 534 companies
in the Drug Manufacturers industry
Industry Median: 24.825 vs LTS:0LB2: 20.49

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Supernus Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.002. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $1.38 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Supernus Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Supernus Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Shiller PE Ratio Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 55.15 38.05 21.39

Supernus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.17 25.35 21.71 21.39 24.32

Competitive Comparison of Supernus Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Shiller PE Ratio falls into.



Supernus Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Supernus Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=28.70/1.38
=20.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Supernus Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.002/131.7762*131.7762
=0.002

Current CPI (Mar. 2024) = 131.7762.

Supernus Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.080 100.560 0.105
201409 -0.060 100.428 -0.079
201412 0.100 99.070 0.133
201503 0.020 99.621 0.026
201506 0.040 100.684 0.052
201509 0.080 100.392 0.105
201512 0.140 99.792 0.185
201603 0.080 100.470 0.105
201606 0.180 101.688 0.233
201609 1.180 101.861 1.527
201612 0.260 101.863 0.336
201703 0.190 102.862 0.243
201706 0.320 103.349 0.408
201709 0.290 104.136 0.367
201712 0.260 104.011 0.329
201803 0.490 105.290 0.613
201806 0.570 106.317 0.706
201809 0.520 106.507 0.643
201812 0.480 105.998 0.597
201903 0.340 107.251 0.418
201906 0.610 108.070 0.744
201909 0.540 108.329 0.657
201912 0.620 108.420 0.754
202003 0.400 108.902 0.484
202006 0.650 108.767 0.788
202009 0.740 109.815 0.888
202012 0.570 109.897 0.683
202103 0.110 111.754 0.130
202106 0.430 114.631 0.494
202109 0.400 115.734 0.455
202112 0.040 117.630 0.045
202203 0.430 121.301 0.467
202206 0.140 125.017 0.148
202209 0.030 125.227 0.032
202212 0.430 125.222 0.453
202303 0.290 127.348 0.300
202306 -0.020 128.729 -0.020
202309 -0.290 129.860 -0.294
202312 0.017 129.419 0.017
202403 0.002 131.776 0.002

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Supernus Pharmaceuticals  (LTS:0LB2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Supernus Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (LTS:0LB2) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (LTS:0LB2) Headlines

No Headlines